Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Synonyms
Fluvoxamina
Fluvoxamine maleate
Fluvoxamine
Fluvoxaminum
Brand Names
Fluvoxamine-50
Act Fluvoxamine
Luvox CR
Dom-fluvoxamine
PMS-fluvoxamine
Ratio-fluvoxamine
Bci Fluvoxamine Tablets
Riva-fluvox
Fluvoxamine Maleate
Novo-fluvoxamine
Fluvoxamine
Gen-fluvoxamine 100mg
Sandoz Fluvoxamine
Fluvoxamine Tablets
PHL-fluvoxamine
Gen-fluvoxamine 50mg
Luvox
Fluvoxamine-100
Riva-fluvox 100mg Tablets
Riva-fluvox 50mg Tablets
Ava-fluvoxamine
Fluvoxamine maleate
Apo-fluvoxamine
Indication
Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) [FDA Label]. Has also been used in the management of bulimia nervosa [A250].
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682